Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinoic acid and cabergoline in ACTH-secreting pituitary adenoma (Cushing's disease)
2019-004019-29Phase 2Terminated
- Sponsor
- Università di Padova
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cabergoline and tretinoin in Corticotropin adenoma (ACTHoma) (3 arms), sponsored by Università di Padova. Primary endpoint: Normalization of urinary free cortisol after monotherapy and combination therapy. Started Oct 2020; status: terminated.
02
Drugs
cabergolinetretinoin
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2019-004019-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004019-29.